Skin Help

Este proyecto fue elaborado para ciertos requerimientos de las personas que desean cuidar su piel, y de esta manera contribuir con la salud, el bienestar físico y mental de las personas. Nuestro negocio consiste en brindar un servicio que le permite al usuario poder realizar una prueba y un escaneo de rostro para identificar su tipo de piel o algunas anomalías comunes que puedan presentar. El canal que usaremos es un aplicativo móvil fácil de usar, sencillo de acceder. Este servicio brindará asesoría sobre productos dermatológicos para el cuidado de la piel. Además, permitirá realizar un test y un escaneo de rostro a los usuarios con la finalidad de obtener un resultado de manera inmediata. Por lo que se estima recibir ingresos por comisiones pagadas por las empresas, mediante este proceso el usuario descarga la App para averiguar información al respecto, adquiriendo uno de los productos o servicios recomendados. Además, se busca obtener ganancias por la cantidad de descargas que se deben generar mes a mes por la web.This project was developed for certain requirements of people who want to take care of their skin, and in this way contribute to the health, physical and mental well-being of people. Our business consists of providing a service that allows the user to perform a test and a face scan to identify their skin type or some common anomalies that they may present. The channel that we will use is an easy-to-use mobile application, easy to access. This service will provide advice on dermatological products for skin care. In addition, it will allow users to perform a test and a face scan in order to obtain an immediate result. For what it is estimated to receive income from commissions paid by companies, through this process the user downloads the App to find out information about it, acquiring one of the recommended products or services. In addition, it seeks to obtain profits for the number of downloads that must be generated month by month through the web.Trabajo de investigació

Mortandad de caprinos por posible intoxicación con insectos escarabajos “siete de oro”, en la Localidad de Copacabana, departamento Tinogasta, Catamarca.

El caso de mortalidad en caprinos ocurrido a fines de febrero del 2023, estuvo circunscripto a un productor de la localidad de Copacabana, dpto. Tinogasta, provincia de Catamarca. Ante la problemática el productor realizó la consulta en la Agencia de Extensión de INTA ubicada en el departamento; generando interconsultas con las Áreas de Producción Animal y Vegetal de la institución y con la finalidad de abordar la problemática.EEA CatamarcaFil: Cortez, Patricia Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Agencia de Extensión Rural Tinogasta; ArgentinaFil: Castro, Ornella Eugenia. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Campo Anexo Santa Cruz; ArgentinaFil: Ojeda Fermoselle, Pablo Matias. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Campo Anexo Santa Cruz; ArgentinaFil: Aybar, Sonia Elizabeth. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca; ArgentinaFil: Gonzalez, Maria Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Campo Anexo Santa Cruz; ArgentinaFil: Almaraz, Sabrina Cristina. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Campo Anexo Santa Cruz; ArgentinaFil: Herrera, Victor Gaspar. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Campo Anexo Santa Cruz; ArgentinaFil: Dominguez, Pablo Martín. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca. Campo Anexo Santa Cruz; ArgentinaFil: Herrera Conegliano, Oscar Ariel. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Catamarca; Argentin

Prevalência de parasitas intestinais em escolares de instituições públicas de primeiro grau da região sul da cidade de Porto Alegre - RS

04

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Internal control in PCR for Mycobacterium tuberculosis: usefulness and improvement of the diagnosis

The aim of this work was to construct and test a plasmidial Internal Control (IC) to detect the inhibition in the PCR test for M. tuberculosis and also its contribution for a Public Health Laboratory routine. The IC was a 600-bp of DNA linked to a plasmid with the same primer sites, allowing the amplification with the 245-bp diagnostic fragment. The amplification of the positive samples rendered the IC and the diagnostic fragment; instead negative samples only showed the IC. A total of 149 tuberculosis samples were studied and introduced the IC to monitor. Results showed 3.3% of the samples without amplification of the IC, suggesting the inhibition. These samples showed results in accordance with the clinical results. The objective of the IC was to identify the false negative results